277 related articles for article (PubMed ID: 17592672)
1. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Ewer MS; O'Shaughnessy JA
Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
6. The cardiac safety of trastuzumab in the treatment of breast cancer.
Chien AJ; Rugo HS
Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
14. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Tripathy D; Seidman A; Keefe D; Hudis C; Paton V; Lieberman G
Clin Breast Cancer; 2004 Oct; 5(4):293-8. PubMed ID: 15507176
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.
Conte B; Montemurro F; Levaggi A; Blondeaux E; Molinelli C; Cardinali B; Poggio F; Buzzatti G; Bighin C; Lambertini M; Del Mastro L
Tumori; 2023 Feb; 109(1):71-78. PubMed ID: 34989265
[TBL] [Abstract][Full Text] [Related]
19. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ; Harris LN; Gelman R; Lester SC; Nunes RA; Kaelin CM; Parker LM; Ellisen LW; Kuter I; Gadd MA; Christian RL; Kennedy PR; Borges VF; Bunnell CA; Younger J; Smith BL; Winer EP
J Clin Oncol; 2003 Jan; 21(1):46-53. PubMed ID: 12506169
[TBL] [Abstract][Full Text] [Related]
20. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
